Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Hospital-Acquired Anemia Affects One-Third of Patients

By LabMedica International staff writers
Posted on 31 May 2017
One in three patients hospitalized for medical problems experience hospital-acquired anemia (HAA), a drop in hematocrit due to the hospitalization, claims a new study.

Conducted by researchers at the University of Texas Southwestern Medical Center and the Parkland Health and Hospital System, the observational cohort study reviewed 11,309 patients discharged between November 1, 2009 and October 30, 2010 from six Texas hospitals, examining the incidence, predictors, and post-discharge outcomes associated with HAA. Patients with anemia on admission or missing hematocrit values were excluded.

The results revealed that one-third of the patients developed HAA - 21.6% with mild HAA; 10.1% with moderate HAA; and 1.4% with severe HAA. The most severe form of HAA--defined as a hematocrit of 27% or less at the time of discharge--was independently associated with a 39% increase in odds of being readmitted or dying within 30 days after hospital discharge. The two strongest potentially modifiable predictors of developing moderate or severe HAA were length of stay and a major procedure. The study was published in the May 2017 issue of the Journal of Hospital Medicine.

“This is the first study of post-discharge adverse outcomes of hospital-acquired anemia among a diverse group of patients who were hospitalized for different reasons,” said lead author Anil Makam, MD, of UT Southwestern. “Reducing blood loss during major surgeries and reducing unnecessary testing during hospital stays may lower a patient's risk of developing severe hospital-acquired anemia, and potentially improve their recovery.”

“This study shines a spotlight on a very common but underappreciated risk of hospitalization, hospital-acquired anemia, which has traditionally been viewed as an incidental change in the red blood count of no significance,” said senior author Professor Ethan Halm, MD, MPH. “However, our results showed that hospital-acquired anemia was associated with worse clinical outcomes after leaving the hospital, so it needs to be taken more seriously.”

Hematocrit is the volume percentage of red blood cells (RBCs) in blood; it is normally 45% for men and 40% for women. It is considered an integral part of the complete blood count (CBC), together with hemoglobin concentration, white blood cell count, and platelet count. Anemia refers to an abnormally low hematocrit, which could indicate life-threatening diseases such as bleeding, leukemia, malnutrition, water intoxication, and more.


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
New
High Performance Centrifuge
CO336/336R
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.